PTPN11 and cancer: Currently, several clinical trials have been initiated to test SHP2 inhibitors, such as BBP-398 plus nivolumab (NCT05375084), RMC-4630 (SHP2-inhibitor) plus LY3214996 (ERK-inhibitor) (NCT04916236), ET0038 (NCT04528836 and NCT05354843), JAB-3068 (NCT03565003), and ERAS-601 (NCT04670679) as monotherapy or combination treatments for different types of cancer.